Capivasertib Plus Paclitaxel Versus Placebo Plus Paclitaxel As First-Line Therapy for Metastatic Triple-Negative Breast Cancer: The PAKT Trial.

Schmid, Peter; Abraham, Jacinta; Chan, Stephen; Wheatley, Duncan; Murray Brunt, Adrian; Nemsadze, Gia; D Baird, Richard; Hee Park, Yeon; S Hall, Peter; Perren, Timothy; C Stein, Robert; Mangel, László; Ferrero, Jean-Marc; Phillips, Melissa; Conibear, John; Cortes, Javier; Foxley, Andrew; C de Bruin, Elza; McEwen, Robert; Stetson, Daniel; Dougherty, Brian; Sarker, Shah-Jalal; Prendergast, Aaron; McLaughlin-Callan, Max; Burgess, Matthew; Lawrence, Cheryl; Cartwright, Hayley; Mousa, Kelly; C Turner, Nicholas

doi:10.1200/jco.19.00368

Public

Capivasertib Plus Paclitaxel Versus Placebo Plus Paclitaxel As First-Line Therapy for Metastatic Triple-Negative Breast Cancer: The PAKT Trial.

Shared by NobleBlocks on Feb 10, 2020 • 12:00 AM UTC

Authors:

Peter Schmid

Jacinta Abraham

Stephen Chan

Abstract

PURPOSE: The phosphatidylinositol 3-kinase (PI3K)/AKT signaling pathway is frequently activated in triple-negative breast cancer (TNBC). The AKT inhibitor capivasertib has shown preclinical activity in TNBC models, and drug sensitivity has been associated with activation of PI3K or AKT and/or deleti...

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!